OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
agreement
OMRF collaborates with GSK to develop novel treatments for severe inflammatory diseases
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
Q BioMed Inc. finalizes license agreement with OMRF, RGCB
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.
